|
Orthologous residues
|
|
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): ‑, STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
F-36P (erythroid), K562 (erythroid)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Src (human)
|
transfection of dominant-negative enzyme, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
Epo
|
|
|
|
increase
|
|
|
PP3
|
Epo
|
|
|
no effect upon treatment-induced increase
|
|
|
PP1
|
Epo
|
|
|
inhibit treatment-induced increase
|
|
|
PP2
|
Epo
|
|
|
inhibit treatment-induced increase
|
|
|
AG490
|
Epo
|
|
|
inhibit treatment-induced increase
|
|
|
